Free Trial

Y-mAbs Therapeutics (YMAB) Competitors

$12.00
+0.25 (+2.13%)
(As of 06/21/2024 09:00 PM ET)

YMAB vs. HRTX, AMRN, AUPH, MRSN, GBIO, AMRX, AMPH, VERA, PTGX, and GMTX

Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Heron Therapeutics (HRTX), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Mersana Therapeutics (MRSN), Generation Bio (GBIO), Amneal Pharmaceuticals (AMRX), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), Protagonist Therapeutics (PTGX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical preparations" industry.

Y-mAbs Therapeutics vs.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.

70.9% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 21.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 6.4% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Heron Therapeutics received 539 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 69.05% of users gave Heron Therapeutics an outperform vote while only 60.71% of users gave Y-mAbs Therapeutics an outperform vote.

CompanyUnderperformOutperform
Y-mAbs TherapeuticsOutperform Votes
119
60.71%
Underperform Votes
77
39.29%
Heron TherapeuticsOutperform Votes
658
69.05%
Underperform Votes
295
30.95%

Y-mAbs Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Y-mAbs Therapeutics has a net margin of -25.64% compared to Heron Therapeutics' net margin of -61.28%. Heron Therapeutics' return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Y-mAbs Therapeutics-25.64% -21.40% -16.91%
Heron Therapeutics -61.28%N/A -37.18%

In the previous week, Heron Therapeutics had 1 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 3 mentions for Heron Therapeutics and 2 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.54 beat Heron Therapeutics' score of 0.94 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Y-mAbs Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Heron Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Y-mAbs Therapeutics currently has a consensus target price of $17.33, indicating a potential upside of 44.44%. Heron Therapeutics has a consensus target price of $6.00, indicating a potential upside of 85.76%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Y-mAbs Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Y-mAbs Therapeutics
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Heron Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Y-mAbs Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs Therapeutics$84.82M6.21-$21.43M-$0.49-24.49
Heron Therapeutics$127.04M3.83-$110.56M-$0.61-5.29

Summary

Heron Therapeutics beats Y-mAbs Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMAB vs. The Competition

MetricY-mAbs TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$526.56M$6.81B$4.92B$8.38B
Dividend YieldN/A2.76%5.25%4.09%
P/E Ratio-24.4916.87145.8216.77
Price / Sales6.21247.122,203.7766.25
Price / CashN/A31.7932.5831.82
Price / Book5.175.654.744.39
Net Income-$21.43M$143.99M$105.56M$214.83M
7 Day Performance2.13%3.62%116.62%2.65%
1 Month Performance-1.80%0.55%115.19%-0.30%
1 Year Performance67.83%-5.85%122.63%1.53%

Y-mAbs Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRTX
Heron Therapeutics
3.7679 of 5 stars
$3.42
+5.9%
$6.00
+75.4%
+166.9%$515.22M$127.04M-5.61126
AMRN
Amarin
0.7143 of 5 stars
$0.73
-3.9%
$1.08
+48.4%
-39.5%$299.83M$306.91M-6.08275Gap Down
AUPH
Aurinia Pharmaceuticals
2.2874 of 5 stars
$5.42
-2.2%
$10.00
+84.5%
-40.1%$773.22M$175.51M-12.60300
MRSN
Mersana Therapeutics
3.4404 of 5 stars
$2.04
flat
$6.29
+208.1%
-30.8%$249.61M$36.85M-1.79123Positive News
GBIO
Generation Bio
2.0361 of 5 stars
$2.70
-7.5%
$8.00
+196.3%
-51.5%$179.63M$5.90M-1.06174
AMRX
Amneal Pharmaceuticals
1.5434 of 5 stars
$6.72
-0.4%
$8.25
+22.8%
+131.3%$2.07B$2.39B-12.007,700
AMPH
Amphastar Pharmaceuticals
4.8582 of 5 stars
$40.05
-1.2%
$66.00
+64.8%
-29.2%$1.96B$644.40M13.861,761
VERA
Vera Therapeutics
0.8365 of 5 stars
$35.53
-0.5%
$42.86
+20.6%
+107.8%$1.94BN/A-17.3351
PTGX
Protagonist Therapeutics
1.2592 of 5 stars
$32.59
+0.4%
$38.00
+16.6%
+16.8%$1.91B$60M13.36112
GMTX
Gemini Therapeutics
0 of 5 stars
$43.54
-2.9%
N/A-18.5%$1.89BN/A-43.5431Gap Down
High Trading Volume

Related Companies and Tools

This page (NASDAQ:YMAB) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners